SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 28
NA - Nord America 19
EU - Europa 13
SA - Sud America 2
Totale 62
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 24
US - Stati Uniti d'America 19
IT - Italia 11
ID - Indonesia 4
BR - Brasile 2
FI - Finlandia 2
Totale 62
Salva come PNG Salva come JPEG
Città #
Singapore 16
Forest City 5
Ashburn 4
Jakarta 4
Arezzo 2
Bologna 2
Brasília 2
Fort Worth 2
Imola 2
Lappeenranta 2
Prineville 2
Sandston 2
Springfield 2
Ferrara 1
Napa 1
Naples 1
Parma 1
Totale 51
Salva come PNG Salva come JPEG
Nome #
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 9
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 8
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 6
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 5
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 5
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 5
A headlight on liquid biopsies: a challenging tool for breast cancer management 3
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 3
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 3
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable? 3
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 2
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 2
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 2
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 2
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 2
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 2
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 2
Anti-endothelin drugs in solid tumors 2
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 2
Monoclonal antibodies in gastrointestinal cancers 2
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 2
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 2
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 2
Cancer and the microbiome: Potential applications as new tumor biomarker 2
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 2
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 2
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 2
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 2
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 2
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 2
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 2
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 2
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 2
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 2
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 2
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 2
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 2
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 2
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 2
Bortezomib: A new pro-apoptotic agent in cancer treatment 2
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 2
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 1
New generation anaplastic lymphoma kinase inhibitors 1
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 1
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 1
Multisciplinary management of patients with liver metastasis from colorectal cancer 1
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 1
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 1
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 1
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 1
Targeted therapies in hepatocellular carcinoma 1
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 1
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 1
How much of familial breast cancer risk is currently explained by the known genes? 1
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 1
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 1
TMB in NSCLC: A Broken Dream? 1
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 1
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 1
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 1
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 1
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 1
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 1
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 1
Fully human antibodies for malignant pleural mesothelioma targeting 1
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 1
What to look for in cell-free DNA from breast cancer patients 1
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 1
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 1
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 1
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 1
Dietary restriction: could it be considered as speed bump on tumor progression road? 1
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 1
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 1
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 1
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 1
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 1
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 1
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 1
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 1
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 1
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 1
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 1
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 1
Sex steroids, carcinogenesis, and cancer progression 1
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 1
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 1
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 1
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 1
Nintedanib in NSCLC: Evidence to date and place in therapy 1
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer 1
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 1
Well-being among Italian medical oncologists: An exploratory study 1
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 1
The application of cancer stem cell model in malignant mesothelioma 1
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 1
Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy 1
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 1
Ramucirumab and its use in gastric cancer treatment 1
MicroRNAs in colorectal cancer stem cells: New regulators of cancer stemness? 1
Totale 171
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024157 0 0 0 0 0 0 0 4 21 3 11 118
2024/202527 27 0 0 0 0 0 0 0 0 0 0 0
Totale 184